Healthcare Business Roundup: StemCells Kicks Off With A Buy, Neuralstem Begins Test

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

StemCells (NASDAQ:STEM) sees its shares initiated by Ascendiant Capital Markets with a Buy along with a $2.60 price target. The analyst firm commented that, “We believe that StemCells is an intriguing speculative small cap investment story. The Company is breaking new ground in its development of novel stem cell therapies.”

Shares of Isis Pharmaceuticals (NASDAQ:ISIS) continue downward from a downgrade to Neutral Wednesday morning at Summer Street, which foresees only a 50 percent chance that the FDA panel approve its hypercholesterolemia drug Kynamro.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Neuralstem (AMEX:CUR) commences testing the safety of its NSI-189 treatment for Major Depressive Disorder with a second set of patients subsequent to receiving FDA approval to do so. The firm says that “There were no surprises” in the first cohort of patients in the Phase Ib study.

Nabi Biopharmaceuticals (NASDAQ:NABI) shares finished the day in the green in the face of its earlier announcement that Phase 2 studies of its smoking-cessation vaccine failed to meet the primary endpoint, which presents another setback for the drug.

Don’t Miss: Here’s How Arena Put Analysts On The Edge of Their Seats.

More Articles About:

To contact the reporter on this story: To contact the editor responsible for this story:

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business